Molecular Metabolism paper describes how eloralintide was discovered and its first-in-human results
MechanismP1Primary public evidencePeer-reviewed publication
On 16 October 2025 Briere and colleagues published the discovery and first-in-human work on eloralintide in Molecular Metabolism. In human cell assays the molecule was about 12-fold more potent at the amylin 1 receptor (AMY1R) than at the calcitonin receptor, and in a single-dose Phase 1 study in 48 healthy participants, body weight at day 29 changed by -2.5% (4 mg) and -4.4% (12 mg) against +0.6% with placebo.
12-fold
Selectivity for AMY1R over the calcitonin receptor in human cell assays
-4.4% vs +0.6%
Day-29 body weight change, 12 mg vs placebo, healthy participants (single-ascending-dose Phase 1)
Background and context
Who wrote it
All 18 authors list Eli Lilly and Company as their affiliation in PubMed. This is the developer reporting on its own molecule.
More than one kind of evidence
The paper combines cell assays, studies in rats and monkeys and a Phase 1 trial. The receptor pattern differed by species. The 12-fold margin quoted on this page is for human AMY1R, while in rat cells both AMY1R and AMY3R responded more strongly than the calcitonin receptor.
Linking the paper to the registry
The paper cites NCT05295940 for its Phase 1 trial. That record describes a two-part study of 148 participants, healthy adults in Part A and adults with overweight in Part B, and posts no results. The paper describes 48 healthy participants, fewer than the 148 registered.
Briere DA et al., Molecular Metabolism, 2025, volume 102, article 102271, via PubMed (PMID 41109426), DOI 10.1016/j.molmet.2025.102271. Trial record: ClinicalTrials.gov NCT05295940, read on 2026-10-15. Registered plans can change.
